This presentation will use case studies to elaborate on the multifaceted optimization required to yield a viable clinical candidate ADC.
ADCs employing different mechanism of action (MOA) payloads will be used as examples to illustrate the need to match target biology with MOA of payload.
There were no changes to permanent program elements or funding guidelines from the 2011 SBIR Reauthorization Act.The full RFP solicitation will be issued on or after July 17, 2017.You can also sign up for an informational webinar for potential offerors in mid-August once details are announced in the RFP.Emphasis will be placed on learning from molecules in clinical development. D., Division of Surgical Oncology, Department of Surgery, Massachusetts General Hospital Mitchell Ho, Ph.Plan to attend to review the vibrant community of therapeutic antibodies and discover the latest trends for future best-in-class drugs. D., Head, Antibody Therapy Section, Laboratory of Molecular Biology, National Cancer Institute, NIH Horacio G. D., Director Biotherapeutics, Center for Therapeutic Innovation (CTI), Pfizer, Inc.